Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Efficacy and Safety Analysis

Background: Pembrolizumab (pembro) is a monoclonal antibody against PD-1 that helps to restore antitumor immune surveillance. KEYNOTE-023 (NCT02036502) is a phase 1 dose-escalation study evaluating safety and efficacy of pembro in combination with lenalidomide (len) and low-dose dexamethasone (dex) in patients with RRMM.

Author(s): 
María-Victoria Mateos, Robert Z. Orlowski, David Samuel DiCapua Siegel, Donna Ellen Reece, Philippe Moreau, Enrique M. Ocio, Jatin J. Shah, Paula Rodríguez-Otero, Nikhil C. Munshi, David Avigan, Joy Yang Ge, Patricia Maria Marinello, Jesus San Miguel; University Hospital of Salamanca/IBSAL, Salamanca, Spain; The University of Texas MD Anderson Cancer Center, Houston, TX; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ; Princess Margaret Cancer Centre, Toronto, ON, Canada; University Hospital Hotel-Dieu, Nantes, France; Clinica Universidad De Navarra, Pamplona, Spain; Dana-Farber Cancer Institute, Boston, MA; Beth Israel Deaconess Medical Center, Boston, MA; Merck & Co., Inc., Kenilworth, NJ; University of Navarra, Pamplona, Spain


ABOUT MARIA V. MATEOS, MD, PhD

Dr. María-Victoria Mateos is an Associate Professor of Hematology and Consultant Physician in the Haematology Department at the University of Salamanca and Director of the Myeloma Unit, where she is responsible for coordinating the Clinical Trials Unit in Salamanca University Hospital’s Hematology Department. She currently serves on the European Hematology Association (EHA) as the Chair of the Scientific Program Committee for the 2019 Congress.

Previous Post
ASCO 2016: Multiple Myeloma Overview -- Dr. Morie Gertz
Next Post
ASCO 2016: PAVO study -- Dr. Saad Usmani

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.